Clinical trials: Adjuvant
Melanoma, Skin Cancer
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00002882
- Testing
- Aldesleukin (IL-2), Recombinant Interferon Alfa (IFN-A), Cisplatin
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- M.D. Anderson Cancer Center
Retinal Telangiectasis, Coats Disease
Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
Coats disease is a predominantly unilateral progressive retinal vascular disease, characterized by retinal telangiectasias with intra- or subretinal exudate deposits, which can lead to retinal detachment and one-sided blindness.
- Trial name
- COATS-VEGF (NCT03940690)
- Testing
- Anti-VEGF injections of bevacizumab, Laser
- Where
- 6 sites in France
- Volunteers
- 18 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild